Key Highlights

  • Cosmos Health (NASDAQ:COSM) ended Tuesday, November 10, 2026 at USD 0.2085, off 22.14% from a calculated previous close of USD 0.2678, among the steepest decliners in a published screener snapshot of 4,625 names.
  • Trading came to 3.22M shares at a relative Volume of 1.69, against an implied average near 1.91M (calculated), worth roughly USD 671 thousand at the close (calculated).
  • The snapshot lists a Market Value of USD 20.98 million, or about 100.6 million shares at the close (calculated), with trailing diluted EPS of USD -0.65, EPS growth of +34.05%, no P/E and a 0.00% dividend yield.
  • The price sits 79.2% under USD 1.00 (calculated). The newest results located, for the third quarter of 2025, showed Revenue up 38% to USD 17.1 million, Gross Profit up 116% to USD 2.6 million and cash of USD 4.63 million.

Why Cosmos Health Fell on November 10 (-22.14%)

Canadian investors scanning US-listed names filed under health technology in the snapshot saw Cosmos Health close its regular session at USD 0.2085, lower by 22.14%. Simple arithmetic yields a calculated previous close of USD 0.2678 for Monday, November 9, 2026, a loss near USD 0.0593 per share. Trading of 3.22M shares at a relative volume of 1.69 implies an average around 1.91M shares (calculated), so activity ran about 69% above the norm, worth roughly USD 671 thousand at the close (calculated). Trailing diluted EPS of USD -0.65 is about 3.1 times the share price (calculated), a ratio that may reflect a different share basis and is unconfirmed. EPS growth of +34.05% points to a narrower loss.

The Rationale: No Catalyst Identified in Published Coverage

After two searches, published coverage showed no company release, filing or analyst action dated November 9 or November 10, 2026, so saying that no catalyst was identified is the accurate position. The newest dated results located are the third quarter 2025 figures in an 8-K filed on November 17, 2025: revenue up 38% to USD 17.1 million, gross profit up 116% to USD 2.6 million, adjusted EBITDA up 74% and cash of USD 4.63 million compared with USD 0.66 million. They are a year old, serving as context and not as a driver. In general terms, a stock priced under USD 1.00 faces Nasdaq's minimum bid price rule, and published coverage mentions an additional 180-day compliance period for the company, although the date was unconfirmed. Selling linked to financing or dilution can also move sub-dollar stocks. These are general mechanisms and not confirmed causes.

Valuation, Liquidity and Risks for Cosmos Health

A market value of USD 20.98 million equals about 0.31 times the annualized third quarter 2025 revenue of USD 68.4 million (calculated), an out-of-date comparison that ignores any change since. No P/E exists because trailing EPS is USD -0.65, and the Dividend Yield is 0.00%. With the stock 79.2% under USD 1.00 at USD 0.2085, a reverse split to restore minimum bid compliance is possible, though none was found. Dilution from share sales, recurring losses and the age of the newest results located are specific risks. Turnover of 3.22M shares is modest in dollar terms at about USD 671 thousand, so a few trades can move the price and spreads can run wide. Nothing here indicates the move will continue.

Where Things Stand

Cosmos Health (NASDAQ:COSM) dropped 22.14% to USD 0.2085 on November 10, 2026, with no catalyst located in published coverage. Trading of 3.22M shares was 1.69 times the average and market value was USD 20.98 million. The price is 79.2% under USD 1.00, which keeps Nasdaq minimum bid risk in view, though that is general context and not a confirmed cause of the decline.